Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $23.90 USD
Change Today -0.32 / -1.32%
Volume 381.3K
MR On Other Exchanges
Symbol
Exchange
New York
Singapore
Mexico
Frankfurt
As of 8:04 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

mindray medical intl ltd-adr (MR) Snapshot

Open
$24.01
Previous Close
$24.22
Day High
$24.22
Day Low
$23.75
52 Week High
03/5/15 - $33.83
52 Week Low
08/24/15 - $23.52
Market Cap
2.8B
Average Volume 10 Days
504.6K
EPS TTM
$1.50
Shares Outstanding
88.2M
EX-Date
03/17/15
P/E TM
16.0x
Dividend
$0.40
Dividend Yield
1.67%
Current Stock Chart for MINDRAY MEDICAL INTL LTD-ADR (MR)

mindray medical intl ltd-adr (MR) Related Businessweek News

View More BusinessWeek News

mindray medical intl ltd-adr (MR) Details

Mindray Medical International Limited develops, manufactures, and markets medical devices worldwide. The company operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. The Patient Monitoring and Life Support Products segment offers monitoring devices that track the physiological parameters of patients, such as heart rate, blood pressure, respiration, and temperature. Its products include single and multiple-parameter monitors; mobile and portable multifunction monitors; central stations that can collect and display multiple patient data on a single screen; electro-cardiogram monitoring devices; and veterinary monitoring devices. This segment also provides anesthesia machines; defibrillators; surgical equipment, including surgical beds, and surgical lights ceiling pendants; syringes and infusion pumps; and ventilators. The In-Vitro Diagnostic Products segment provides data and analysis on blood, urine, and other bodily fluid samples for clinical diagnosis and treatment; and in-vitro diagnostic products for laboratories, clinics, and hospitals to perform analysis to detect and quantify substances in patient samples. Its product portfolio consists of hematology analysis, biochemistry analysis, immunoassay analysis, flow cytometric analysis, coagulation analysis, urine sediment analysis and microbiology analysis; and reagents used in in-vitro diagnostic products. The Medical Imaging Systems segment offers ultrasound systems used in medical fields, such as urology, gynecology, obstetrics, and cardiology; digital radiography systems; and magnetic resonance imaging systems. The company also provides orthopedic products, endoscope devices, and healthcare IT solutions. It markets and sells its products through distributors, as well as directly to hospitals and government agencies. The company was founded in 1991 and is headquartered in Shenzhen, the People’s Republic of China.

8,200 Employees
Last Reported Date: 08/10/15
Founded in 1991

mindray medical intl ltd-adr (MR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mindray medical intl ltd-adr (MR) Key Developments

Mindray Medical International Limited Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Full Year 2015

Mindray Medical International Limited reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net revenues of USD 336.817 million compared to USD 334.452 million a year ago. Income from operations was USD 49.977 million compared to USD 64.442 million a year ago. Net income was USD 42.668 million compared to USD 61.166 million a year ago. Net income attributable to the company was USD 41.161 million compared to USD 59.618 million a year ago. Diluted earnings per share was USD 0.35 compared to USD 0.50 a year ago. Net cash provided by operating activities was USD 62.085 million compared to USD 84.599 million a year ago. Capital expenditures were USD 20.316 million compared to USD 23.176 million a year ago. Non-GAAP net income attributable to the company’s shareholders was USD 49.496 million compared to USD 66.219 million a year ago. Non-GAAP diluted earnings per share was USD 0.42 compared to USD 0.56 a year ago. Non-GAAP operating income was USD 59.264 million compared to USD 71.647 million a year ago. EBIT was USD 49.378 million compared to USD 62.679 million a year ago. EBITDA was USD 64.779 million compared to USD 76.950 million a year ago. Non-GAAP operating income declined 17.3% year-over-year, primarily as a result of lower sales growth rate and the decline in gross margin, as well as higher R&D and G&A expenses. For the six months, the company reported net revenues of USD 609.281 million compared to USD 599.223 million a year ago. Income from operations was USD 80.915 million compared to USD 95.710 million a year ago. Net income was USD 76.482 million compared to USD 98.127 million a year ago. Net income attributable to the company was USD 73.335 million compared to USD 95.256 million a year ago. Diluted earnings per share was USD 0.62 compared to USD 0.81 a year ago. Net cash provided by operating activities was USD 99.077 million compared to USD 104.265 million a year ago. Capital expenditures were USD 51.096 million compared to USD 51.051 million a year ago. Non-GAAP net income attributable to the company’s shareholders was USD 88.953 million compared to USD 112.273 million a year ago. Non-GAAP diluted earnings per share was USD 0.75 compared to USD 0.95 a year ago. Non-GAAP operating income was USD 198.266 million compared to USD 113.946 million a year ago. EBIT was USD 79.561 million compared to USD 94.433 million a year ago. EBITDA was USD 110.302 million compared to USD 122.911 million a year ago. The company now expects its full year 2015 net revenues to grow by a low-single-digit percentage over its full year 2014 net revenues. The company has revised its full year 2015 non-GAAP net income and now expects it to decrease by around 30% over its full year 2014 non-GAAP net income. This revision is due to lower revenue guidance and lower interest income. The non-GAAP net income guidance continues to assume the 2015 payments related to the recently announced employee incentive and talent retention program will be distributed half in equity based compensation and half in cash. The non-GAAP net income guidance also excludes the tax benefits related to the nationwide key software enterprise status and projects a corporate income tax rate of 15% applicable to the Shenzhen subsidiary. The company expects its capital expenditure for full year 2015 to be around USD 150 million.

Mindray Medical International Limited to Report Q2, 2015 Results on Aug 10, 2015

Mindray Medical International Limited announced that they will report Q2, 2015 results at 5:00 PM, China Standard Time on Aug 10, 2015

Mindray Medical International Limited, Q2 2015 Earnings Call, Aug 11, 2015

Mindray Medical International Limited, Q2 2015 Earnings Call, Aug 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MR:US $23.90 USD -0.32

MR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CAS Medical Systems Inc $1.17 USD 0.00
Hutchinson Technology Inc $1.44 USD -0.06
Masimo Corp $39.64 USD -0.99
OSI Systems Inc $72.26 USD -0.78
Sysmex Corp ¥7,070 JPY +30.00
View Industry Companies
 

Industry Analysis

MR

Industry Average

Valuation MR Industry Range
Price/Earnings 16.8x
Price/Sales 2.1x
Price/Book 1.7x
Price/Cash Flow 16.6x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MINDRAY MEDICAL INTL LTD-ADR, please visit www.mindray.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.